Patient Experience of MR-guided Radiotherapy using a 1.5T MR-Linac
Jasmijn Westerhoff,
The Netherlands
OC-0133
Abstract
Patient Experience of MR-guided Radiotherapy using a 1.5T MR-Linac
Authors: Jasmijn Westerhoff1, Sophie de Mol van Otterloo1, Tessa Leer2, Lois Daamen1, Reijer Rutgers1, Lieke Meijers1, Martijn Intven2, Helena Verkooijen1
1University Medical Centre Utrecht, Division of Imaging and Oncology, Utrecht, The Netherlands; 2University Medical Centre Utrecht, Division of Imaging and Oncology, Utrecht , The Netherlands
Show Affiliations
Hide Affiliations
Purpose or Objective
The 1.5 Tesla MR-linac
device (Elekta Stockholm, Sweden) is a combination of a diagnostic 1.5 T MRI
scanner and 7MV linear accelerator and enables MR-guided radiotherapy (MRgRT)
through daily adjustment of treatment plans based on the actual MRI visualized anatomy. Adaptive treatments enable the use of smaller
margins thereby including less organs at risk in the irradiated area which
potentially reduces toxicity in patients and enables safe dose escalation.
However, due to daily adaptation, treatment times are longer compared to
conventional treatment and patients need to lie still in a confined bore during
treatment delivery. This study aims to evaluate patients’ on-table experience
of MRgRT on a 1.5T MR-linac.
Material and Methods
All
patients treated with a daily adaptive workflow on the MR-Linac at our
institution from November 2020 until April 2021, were eligible for inclusion.
Patient experience was captured after the third or fourth treatment fraction by means of an adaptation of a validated questionnaire by McNair et al. This
questionnaire includes items on physical and psychological coping, and
situational and informational needs. Answers to the statements were given on a
5 point Likert scale from strongly disagree to strongly agree.
Results
In
total 83 patients were included in this survey study. Patients were primarily
male (n=73, 88%), and the median age of participants was 70 years (range 52-90).
The most frequent treatment indications were prostate cancer (n=54, 65%), oligometastatic lymph
node (n=9, 11%) and pancreas (n=8, 10%). The median number of fractions was five
(range 3-17). Responses
to the statements were generally favorable (Figure 1). Ninety percent of
patients (n=82) (strongly) agreed to the statement of feeling calm during
treatment on MR-Linac. Five (6%) and seven (8%) patients were uncomfortable in
the treatment position or on the table respectively. Eight patients (10%) needed more information prior to their
treatment and two (2%) patients felt they needed more information during
treatment. Four (5%) patients answered (strongly) agreed to ‘I wanted to come
out of the treatment machine during my treatment’. Twenty-two (27%) patients
felt tingling sensations during their treatment.
Conclusion
Treatment
on the MR-Linac is generally well tolerated. Most patients do not find
treatment position uncomfortable, feel sufficiently informed before and during
their treatment and tolerate longer treatment times. One in four patients
reported tingling sensations during treatment, which warrants further
investigation.